Risk Benefit Analysis in Therapies for the Diseases and Disabilities of Aging - Panel Discussion
Today, the translation of healthcare innovations into patient outcomes is an inherently multi-stakeholder effort. Consequently, there is a major need to maintain rigor and independence in the regulation of healthcare innovations, while improving regulatory transparency and opportunities for multi-stakeholder input to accommodate fundamental changes in the life-science ecosystem and global healthcare demands. A key strategy in this endeavor is the development and utilization of novel risk-benefit appraisal methodologies, leveraging advances in patient reported outcomes (PROMS), stratified medicines – including ‘big data’ and risk management methodologies utilized presently in other industries.
• David Brindley, Research Fellow, University of Oxford/Center for the Advancement of Sustainable Medical Innovation (Moderator)
• Richard Barker, Director, Center for the Advancement of Sustainable Medical Innovation
• Chris Hornsby, Head of Model Development, Life Risks, Risk Management Solutions, Inc.
• Brock Reeve, Executive Director, Harvard Stem Cell Institute